Key result
Antiplatelet pretreatment in NSTE-ACS may lower ischemic events but increases bleeding and CABG delays.
Why the study?
Antiplatelet pretreatment in patients with NSTE-ACS is controversial due to uncertain balance between ischaemic benefit and bleeding risk, especially with variable timing to coronary angiography.
Does antiplatelet pretreatment reduce ischemic events without unacceptably increasing bleeding risk in patients with NSTE-ACS?
Does antiplatelet pretreatment reduce ischemic events without unacceptably increasing bleeding risk in patients with NSTE-ACS?
While routine P2Y12 inhibitor pretreatment is not recommended for NSTE-ACS patients undergoing early invasive angiography, it may offer ischemic benefits without prohibitive bleeding risks when access to angiography is delayed beyond 24 hours.
Pretreatment decisions in delayed NSTE-ACS angiography remain uncertain; leaves open optimal strategy pending randomized trials.
Antiplatelet pretreatment in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) is controversial. It is vital that the risk of ischaemia and the risk of haemorrhage are both considered when managing this patient group. Current clinical guidelines do not recommend routine pretreatment in patients presenting with NSTE-ACS who are having coronary angiography within 24 hours. However, a significant portion of these patients will not have coronary angiography until after 24 hours. Pretreatment with antiplatelets may reduce the risk of ischaemic events, but it is associated with bleeding and delays to coronary artery bypass grafting, and it may be deleterious in patients with diagnoses other than NSTE-ACS, such as acute aortic syndromes, pulmonary embolism or intracranial bleeds. This review analyses the most important studies assessing antiplatelet pretreatment in NSTE-ACS.
No takes yet. Share an insight, caveat, or question.
Torres-Ruiz et al. (2026) conducted a review in Non-ST elevation acute coronary syndrome (NSTE-ACS). Antiplatelet pretreatment was evaluated. Antiplatelet pretreatment in NSTE-ACS may reduce ischemic events but is associated with bleeding and delays to coronary artery bypass grafting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: